Clinical Policy: Gemtuzumab Ozogamicin (Mylotarg)

Reference Number: LA.PHAR.358
Effective Date:
Last Review Date: 06.25.23
Line of Business: Medicaid

Coding Implications
Revision Log

See Important Reminder at the end of this policy for important regulatory and legal information.

****Please note: This policy is for medical benefit****

Description

Gemtuzumab ozogamicin (Mylotarg™) is a CD33 directed antibody and cytotoxic drug conjugate.

FDA Approved Indication(s)

Mylotarg is indicated for the treatment of:

- Newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 1 month and older
- Relapsed or refractory CD33-positive AML in adults and in pediatric patients 2 years and older

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Louisiana Healthcare Connections® that Mylotarg is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Acute Myeloid Leukemia (must meet all)**:**

1. Diagnosis of CD33-positive AML;
2. Prescribed by or in consultation with an oncologist or hematologist;
3. Member meets (a or b):
   a. Age ≥ 1 month with newly diagnosed disease;
   b. Age ≥ 2 years with relapsed or refractory disease;
4. Mylotarg is prescribed as one of the following (a, b, or c):
   a. As combination therapy with daunorubicin and cytarabine for newly diagnosed disease: up to 5 doses;
   b. As single-agent therapy for newly diagnosed disease: up to 10 doses;
   c. As single-agent thearpy for relapsed or refractory disease: up to 3 doses;
5. Request meets one of the following (a, b, c, d, or e):*
   a. Age 1 month to < 18 years: Newly diagnosed disease as combination therapy with standard chemotherapy (i and ii):
      i. Induction - 1 cycle (1 vial): dose does not exceed 0.1 mg/kg (body surface area [BSA] < 0.6 m^2) or 3 mg/m^2 (BSA ≥ 0.6 m^2) given once;

ii. Intensification - 1 cycle (1 vial): dose does not exceed 0.1 mg/kg (BSA < 0.6 m^2) or 3 mg/m^2 (BSA ≥ 0.6 m^2) given once;

b. Age ≥ 18 years: Newly diagnosed disease as combination therapy with daunorubicin and cytarabine (i and ii):
   i. Induction - 1 cycle (3 vials): dose does not exceed 3 mg/m^2 on Days 1, 4, and 7;
   ii. Consolidation - 2 cycles (2 vials): dose does not exceed 3 mg/m^2 on Day 1 of each cycle;

c. Age ≥ 18 years: Newly diagnosed disease as single-agent therapy (i and ii):
   i. Induction - 1 cycle: dose does not exceed 6 mg/m^2 on Day 1, and 3 mg/m^2 on Day 8;
   ii. Continuation therapy - 8 cycles: dose does not exceed 2 mg/m^2 on Day 1 of each cycle;

d. Age ≥ 2 years: Relapsed or refractory disease (single-agent regimen): single course: dose does not exceed 3 mg/m^2 on Days 1, 4, and 7 (3 vials);

e. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN.*

Approval duration: 12 months

B. Acute Promyelocytic Leukemia (off-label) (must meet all)**:**

1. Diagnosis of acute promyelocytic leukemia;
2. Prescribed by or in consultation with an oncologist or hematologist;
3. Age ≥ 18 years;
4. Mylotarg is prescribed for no more than 10 doses total;
5. Dose is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).*

**Prescribed regimen must be FDA-approved or recommended by NCCN.*

Approval duration: 12 months

C. Other diagnoses/indications (must meet 1 or 2)**:**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy LA.PMN.53

II. Continued Therapy

A. All Indications in Section I (must meet all)**:**

1. Currently receiving medication via Louisiana Healthcare Connections benefit, or documentation supports that member is currently receiving Mylotarg for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;

3. For AML, member has NOT received the maximum recommended doses as described below (a, b or c):
   a. As combination therapy with daunorubicin and cytarabine for newly diagnosed disease: up to 5 doses;
   b. As single-agent therapy for newly diagnosed disease: up to 10 doses;
   c. As single-agent thearpy for relapsed or refractory disease: up to 3 doses;
4. For acute promyelcytic leukemia, member has not received ≥ 10 doses;
5. If request is for a dose increase, request meets one of the following (a, b, c, d, or e):*
   a. Age 1 month to < 18 years: Newly diagnosed disease as combination therapy with standard chemotherapy (i and ii):
      i. Induction - 1 cycle (1 vial): dose does not exceed 0.1 mg/kg (body surface area [BSA] < 0.6 m^2) or 3 mg/m^2 (BSA ≥ 0.6 m^2) given once;
      ii. Intensification - 1 cycle (1 vial): dose does not exceed 0.1 mg/kg (BSA < 0.6 m^2) or 3 mg/m^2 (BSA ≥ 0.6 m^2) given once;
   b. Age ≥ 18 years: Newly diagnosed disease as combination therapy with daunorubicin and cytarabine (i and ii):
      i. Induction - 1 cycle (3 vials): dose does not exceed 3 mg/m^2 on Days 1, 4, and 7;
      ii. Consolidation - 2 cycles (2 vials): dose does not exceed 3 mg/m^2 on Day 1 of each cycle;
   c. Age ≥ 18 years: Newly diagnosed disease as single-agent therapy (i and ii):
      i. Induction - 1 cycle: dose does not exceed 6 mg/m^2 on Day 1, and 3 mg/m^2 on Day 8;
      ii. Continuation therapy - 8 cycles: dose does not exceed 2 mg/m^2 on Day 1 of each cycle;
   d. Age ≥ 2 years: Relapsed or refractory disease (single-agent regimen): single course: dose does not exceed 3 mg/m^2 on Days 1, 4, and 7 (3 vials);
   e. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

   **Prescribed regimen must be FDA-approved or recommended by NCCN.*

   Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2)**:**
1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy LA.PMN.53

III. Diagnoses/Indications for which coverage is NOT authorized:

A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – LA.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

AML: acute myeloid leukemia
BSA: body surface area
FDA: Food and Drug Administration
NCCN: National Comprehensive Cancer Center

Appendix B: Therapeutic Alternatives

Not applicable

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): hypersensitivity to Mylotarg or any of its components
- Boxed warning(s): hepatotoxicity

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
AML newly-diagnosed (combination regimen)	Adults: *Induction:* 3 mg/m^2 IV (up to one 4.5 mg vial) on Days 1, 4, and 7 in combination with daunorubicin and cytarabine. If a second induction cycle is required, do NOT administer Mylotarg. *Consolidation:* 3 mg/m^2 IV on Day 1 (up to one 4.5 mg vial) in combination with daunorubicin and cytarabine for 2 cycles. Pediatric patients ≥ 1 month: • BSA ≥ 0.6 m^2: 3 mg/m^2 IV • BSA < 0.6 m^2 : 0.1 mg/kg IV	*Induction:* 4.5 mg/dose (1 cycle) *Consolidation:* 4.5 mg/dose (2 cycles) *Induction pediatric*: 1 cycle *Consolidation pediatric*: 1 cycle
AML newly-diagnosed (single-agent regimen)	Adults: *Induction:* 6 mg/m^2 IV on Day 1 and 3 mg/m^2 on Day 8 for 1 cycle *Continuation:* 2 mg/m^2 IV on Day 1 every 4 weeks for up to 8 cycles	*Induction:* 6 mg/m^2/dose (1 cycle) *Maintenance:* 2 mg/m^2/dose every 4 weeks (8 cycles)
AML relapsed or refractory (single-agent regimen)	Age ≥ 2 years: 3 mg/m^2 IV (up to one 4.5 mg vial) on Days 1, 4, and 7 for 1 cycle	4.5 mg/dose (1 cycle)

VI. Product Availability

Single-dose vial: 4.5 mg

VII. References

1. Mylotarg Prescribing Information. Wyeth Pharmaceuticals Inc.; Philadelphia, PA. August 2021. Available at: https://www.pfizerpro.com/product/mylotarg. Accessed August 1, 2022.

2. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at: http://www.nccn.org/professionals/drug_compendium. Accessed August 1, 2022.
3. National Comprehensive Cancer Network. Acute Myeloid Leukemia Version 2.2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf. Accessed August 1, 2022.

Coding Implications
Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J9203	Injection, gemtuzumab ozogamicin, 0.1 mg

Reviews, Revisions, and Approvals	Date	LDH Approval Date
Converted Corporate to local policy	06.25.23	

Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.